Terray Therapeutics utilizes a novel spatially encoded screening and optimization platform (tArray) to develop treatments for historically intractable causes of human disease. The company is based in Pasadena, California.
Prior to co-founding Terray Therapeutics, Jacob ran an NIH-funded lab at City of Hope, where he was an associate professor. Jacob received his Ph.D. in organic chemistry from Caltech where he studied with Nobel Laureate Bob Grubbs. Jacob’s postdoctoral training focused on synthetic chemistry and nanotechnology at MIT and Rice University. He received a BA in chemistry from Harvard University (magna cum laude).
Head of Biology
Prior to joining Terray Therapeutics, Vanessa was Vice President of Biology at Rigel Pharmaceuticals. In this role, she was responsible for leading all preclinical research programs from target identification to lead candidate selection and managed the in vitro biology and in vivo pharmacology teams. Vanessa received her Ph.D. in Immunology from the University of Cambridge and was a Post-Doctoral Research Scientist at Rhone-Poulenc Rorer, Oxford University’s Institute of Molecular Medicine, and UCSF.
Head of Computational and Data Sciences
Prior to joining Terray Therapeutics, Narbe was a Senior Scientist at Amgen. In this role, he was responsible for supporting all aspects of computational small molecule drug discovery, including the development of advanced quantum mechanics and machine learning methods, as well as cloud-based solutions to support high-throughput, data-driven workflows. He received his Ph.D. in Quantum Chemistry from UC Berkeley, and was a postdoc in Chemical Physics at Caltech.
Prior to co-founding Terray Therapeutics, Eli spent more than 10 years working in private equity. Most recently, Eli worked at Parthenon Capital Partners, an operationally focused private equity firm. Prior to Parthenon, Eli worked at Irving Place Capital and Lehman Brothers. He holds an MBA from Stanford University and a BA with honors from the London School of Economics.